Novel HPLC-based assay for measuring thymidine kinase activity as a cancer biomarker

Nikolai Zhelev; Elena Kuzmanova; Marilena Spanou

doi:10.1016/j.jbiotec.2017.06.1079

Abstract

Thymidine kinase (TK) has been validated as a serum-derived, tumour-associated marker for a number of malignancies and estimation of TK activity in serum has proved useful for clinical diagnosis and monitoring of therapy. However, the use of this biomarker in the clinical practice is constrained by the lack of an automatable easy-to-perform assay. We have developed and validated a novel HPLC-based assay for measuring thymidine kinase activity in biological samples. This assay is cheaper, easy to perform and does not depend on the use of expensive antibodies or isotopes. The TK assay has been evaluated with samples from breast cancer patients.

Original language	English
Pages (from-to)	S81
Number of pages	1
Journal	Journal of Biotechnology
Volume	256
Issue number	suppl
Early online date	16 Aug 2017
DOIs	https://doi.org/10.1016/j.jbiotec.2017.06.1079
Publication status	Published - 30 Aug 2017
Event	European biotechnology Congress 2017 - Rixos Libertas, Dubrovnik, Croatia Duration: 25 May 2017 → 27 May 2017 http://eurobiotech2017.eu/?p=Home

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jbiotec.2017.06.1079

Cite this

@article{54ed2fb3a00f49a3894425bd193548ef,

title = "Novel HPLC-based assay for measuring thymidine kinase activity as a cancer biomarker",

abstract = "Thymidine kinase (TK) has been validated as a serum-derived, tumour-associated marker for a number of malignancies and estimation of TK activity in serum has proved useful for clinical diagnosis and monitoring of therapy. However, the use of this biomarker in the clinical practice is constrained by the lack of an automatable easy-to-perform assay. We have developed and validated a novel HPLC-based assay for measuring thymidine kinase activity in biological samples. This assay is cheaper, easy to perform and does not depend on the use of expensive antibodies or isotopes. The TK assay has been evaluated with samples from breast cancer patients.",

author = "Nikolai Zhelev and Elena Kuzmanova and Marilena Spanou",

year = "2017",

month = aug,

day = "30",

doi = "10.1016/j.jbiotec.2017.06.1079",

language = "English",

volume = "256",

pages = "S81",

journal = "Journal of Biotechnology",

issn = "0168-1656",

publisher = "Elsevier Science B.V.",

number = "suppl",

note = "European biotechnology Congress 2017 ; Conference date: 25-05-2017 Through 27-05-2017",

url = "http://eurobiotech2017.eu/?p=Home",

}

TY - JOUR

T1 - Novel HPLC-based assay for measuring thymidine kinase activity as a cancer biomarker

AU - Zhelev, Nikolai

AU - Kuzmanova, Elena

AU - Spanou, Marilena

PY - 2017/8/30

Y1 - 2017/8/30

N2 - Thymidine kinase (TK) has been validated as a serum-derived, tumour-associated marker for a number of malignancies and estimation of TK activity in serum has proved useful for clinical diagnosis and monitoring of therapy. However, the use of this biomarker in the clinical practice is constrained by the lack of an automatable easy-to-perform assay. We have developed and validated a novel HPLC-based assay for measuring thymidine kinase activity in biological samples. This assay is cheaper, easy to perform and does not depend on the use of expensive antibodies or isotopes. The TK assay has been evaluated with samples from breast cancer patients.

AB - Thymidine kinase (TK) has been validated as a serum-derived, tumour-associated marker for a number of malignancies and estimation of TK activity in serum has proved useful for clinical diagnosis and monitoring of therapy. However, the use of this biomarker in the clinical practice is constrained by the lack of an automatable easy-to-perform assay. We have developed and validated a novel HPLC-based assay for measuring thymidine kinase activity in biological samples. This assay is cheaper, easy to perform and does not depend on the use of expensive antibodies or isotopes. The TK assay has been evaluated with samples from breast cancer patients.

U2 - 10.1016/j.jbiotec.2017.06.1079

DO - 10.1016/j.jbiotec.2017.06.1079

M3 - Meeting Abstract

SN - 0168-1656

VL - 256

SP - S81

JO - Journal of Biotechnology

JF - Journal of Biotechnology

IS - suppl

T2 - European biotechnology Congress 2017

Y2 - 25 May 2017 through 27 May 2017

ER -

Novel HPLC-based assay for measuring thymidine kinase activity as a cancer biomarker

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this